Instruction for use: Fosfestrol (Phosphoestrolum)I want this, give me price
Estrogens, gestagens; Their homologues and antagonists
Antineoplastic hormonal agents and hormone antagonists
Code CAS 522-40-7
Nosological classification (ICD-10)
C61 Malignant neoplasm of prostate
Adenocarcinoma of the prostate, Hormone-dependent prostate cancer, Hormone-Resistant Prostate Cancer, Malignant tumor of prostate, Malignant neoplasm of prostate, Carcinoma of the prostate, Locally-distributed non-metastatic prostate cancer, Locally advanced prostate cancer, Locally spread prostate cancer, Metastatic prostatic carcinoma, Metastatic prostate cancer, Metastatic hormone-resistant prostate cancer, Non-metastatic prostate cancer, Incompatible prostate cancer, Prostate Cancer, Prostate cancer, Common prostate cancer, Testosterone-Depot Prostate Cancer
E28 Ovarian dysfunction
Dysfunction of the sex glands, Abnormal ovarian function, Non-functioning ovaries, Primary dysfunction of the ovaries, Decreased function of the sex glands, Estrogen insufficiency
Characteristics of Fosfestrol
White or white with a creamy shade of fine crystalline powder, soluble in water, insoluble in alcohol.
The pharmacological action is estrogenic.
Strongly binding to the cytoplasmic receptors of sex hormones, interferes with the realization of androgen effects in patients with androgen-dependent neoplastic processes (adenocarcinoma of the prostate gland). This leads to a slowdown in the growth of the primary tumor and inhibits metastases in the bones. Quickly absorbed. Metabolised in the liver, most of it is secreted by bile into the intestines, from which it is reabsorbed (or excreted with feces), a small part is excreted by the kidneys.
Application of Fosfestrol
Adenocarcinoma (including metastasizing) of the prostate (palliative treatment), insufficiency of estrogenic function.
Tumors of the breast, estrogen-dependent neoplastic processes, liver damage, thrombophlebitis and thromboembolism.
Induction of the development of neoplastic processes in the genitals (in women), liver, exacerbation of cholelithiasis, thromboembolism, hypertension, decreased glucose tolerance, hypercalcemia, enlargement and thickening of the mammary glands, dyspeptic phenomena, cholestatic hepatitis, headache, dizziness, depression, edema, Changes in body weight, allergic skin rashes.
Routes of administration
Inside, in / in (intravenously).